Methodological and conceptual issues in the use of the elevated plus-maze as a psychological measurement instrument of animal anxiety-like behavior

Neuroscience and Biobehavioral Reviews

Volumn 25, Issue 3, 2001, Pages 275-286

  Wall, P M ^a   Messier, Claude ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Animal anxiety measurement; Elevated plus maze; Factorial validity of a 2 factor underlying structure; Methodological and conceptual issues

Indexed keywords

ANXIETY NEUROSIS; ARTICLE; CLINICAL FEATURE; CONCEPT FORMATION; DEFENSIVE BEHAVIOR; ETHOLOGY; FACTORIAL ANALYSIS; MAZE TEST; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RISK ASSESSMENT;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; HUMANS; MODELS, PSYCHOLOGICAL;

EID: 0034980121     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(01)00013-6     Document Type: Article

References (102)

1. Biological bases of anxiety
2. The relation between fear induced by novel stimulation and exploratory behavior
3. Emotion: Clues from the brain
4. Clinical anxiety and its treatment
5. Ethologically-based animal models of anxiety disorders
6. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety
7. Attack and defense in rodents as ethoexperimental models for the study of emotion
8. Antipredator defensive behaviors in a visible burrow system
9. The characterization and modelling of antipredator defensive behavior
10. Diazepam changes risk assessment in an anxiety/defense test battery
11. Behavioral correlates of chronic dominance-subordination relationships of male rats in a seminatural situation
12. Evidence for differential effects of 8-OH-DPAT on male and female rats in the Anxiety/Defense Test Battery
13. Defense system psychopharmacology: An ethological approach to the pharmacology of fear and anxiety
14. Benzodiazepine and sterotonergic modulation of antipredator and conspecific defense
15. Effects of alpha-adrenoceptor agonists and antagonists in a maze- exploration model of 'fear'-motivated behavior
16. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs
17. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
18. The use of a plus-maze to measure anxiety in the mouse
19. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze
20. Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behavior of mice in the elevated plus-maze
21. Influence of social isolation, gender, strain, and prior novelty on plus-maze behavior in mice
22. Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors
23. Influence of prior maze experience on behavior and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice
24. Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test
25. Anxiety, defence and the elevated plus-maze
26. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: Comparison with haloperidol
27. Dopamine D1 and D2 receptor ligands modulate the behavior of mice in the elevated plus-maze
28. Modulation of plus-maze behavior in mice by the preferential D3- receptor agonist 7-OH-DPAT
29. Ethological confirmatory factor analysis of anxiety-like behavior in the murine elevated plus-maze
30. Ethopharmacological analysis of rat behavior on the elevated plus-maze
31. The influence of open arm ledges and maze experience in the elevated plus-maze
32. Responses of Swiss-Webster mice to repeated plus-maze experience: Further evidence for a qualitative shift in emotional state?
33. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety
34. Differences in fear motivated behaviors among inbred mouse strains
35. Environmental factors in the etiology of anxiety
36. Phenomenology and course of generalised anxiety disorder
37. Advances in the psychosocial treatment of anxiety disorders. Implications for national health care
38. Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders
39. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey
40. Generalized anxiety disorder in primary care: The precursor/modifier pathway to increased health care utilization
41. The empirical basis of generalized anxiety disorder
42. Generalized anxiety and generalized anxiety disorder: Description and reconceptualization
43. An inventory for measuring clinical anxiety: Psychometric properties
44. Ethological research in clinical psychiatry: The study of nonverbal behavior during interviews
45. 5-HT3-like receptors in the rat medial prefrontal cortex: Further pharmacological characterization
46. PD135158, a CCK-B antagonist, reduces 'state,' but not 'trait' anxiety in mice
47. Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze
48. Comparison between the behavioral effects of septal and hippocampal lesions: A review
49. Trial 2 in the elevated plus-maze: A different form of fear?
50. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries
51. Utility of ethological analysis to overcome locomotor confounds in elevated maze models of anxiety
52. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone
53. Blockade of effect of stress on risk assessment behavior in mice by a beta-1 adrenoceptor antagonist
54. Acute stress disrupts risk assessment behavior in mice
55. Rat (Rattus norvegicus) defensive behavior in total darkness: Risk-assessment function of defensive burying
56. Lasting effects on rodent anxiety of a single exposure to a cat
57. An ethopharmacological analysis of selective activation of 5-HT1A receptors: The mouse 5-HT1A syndrome
58. Neurotransmitters, anxiety and benzodiazepines: A behavioral review
59. Anxiolytic profiles of alprazolam and ethanol in the elevated plus-maze test and the early acquisition of shuttlebox avoidance
60. The lateral amygdaloid nucleus: Sensory interface of the amygdala in fear conditioning
61. Acquisition of contextual Pavlovian fear conditioning is blocked by application of an NMDA receptor antagonist D,L-2-amino-5- phosphonovaleric acid to the basolateral amygdala
62. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research
63. Use of the elevated plus maze in the search for novel anxiolytic agents
64. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety
65. Effect of isolation on brain monoamines and the behavior of mice in tests of exploration, locomotion, anxiety and behavioral 'despair'
66. Intra-hippocampal buspirone in animal models of anxiety
67. Role of resocialization and of 5-HT1A receptor activation on the anxiogenic effects induced by isolation in the elevated plus-maze test
68. Differential interactions between ethanol and Ro 15-4513 on two anxiety tests in rats
69. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze
70. Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behavior on the elevated X-maze
71. Structure of the mouse behavior on the elevated plus-maze test of anxiety
72. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity
73. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone
74. Effects of diazepam on behavioral and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience
75. Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan
76. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze
77. The interplay of learning and anxiety in the elevated plus-maze
78. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze
79. Neural plasticity, neuropeptides and anxiety in animals - Implications for understanding and treating affective disorder following traumatic stress in humans
80. Antinociceptive effects of elevated plus-maze exposure: Influence of opiate receptor manipulations
81. Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioral responses to the elevated plus-maze in mice
82. U-69,593 microinjection in the infralimbic cortex reduces anxiety and enhances spontaneous alternation memory in mice
83. Tolerance to acut anxiolysis but no withdrawal anxiogenesis in mice treated chronically with 5-HT1A receptor antagonist, WAY 100635
84. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze
85. On the equivalence of factors and components
86. Common factor analysis versus component analysis: Some well and little known facts
87. Component analysis versus common factor analysis: A Monte Carlo study
88. The Beck Depression Inventory: Testing and cross-validating a hierarchical factor structure for nonclinical adolescents
89. Relation of sample size to the stability of component patterns
90. Some factors affecting the success of specification searches in covariance structure modeling
91. Specification searches in covariance structure modeling
92. Concurrent modulation of anxiety and memory
93. Infralimbic muscarinic M1 receptors modulate anxiety-like behavior and spontaneous working memory in mice